(Q44552532)

English

In vitro activity of SPD754, a new deoxycytidine nucleoside reverse transcriptase inhibitor (NRTI), against 215 HIV-1 isolates resistant to other NRTIs

scientific article published in January 2005

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

In vitro activity of SPD754, a new deoxycytidine nucleoside reverse transcriptase inhibitor (NRTI), against 215 HIV-1 isolates resistant to other NRTIs (English)

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

author name string

Richard C Bethell

1

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

Yolanda S Lie

2

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

Neil T Parkin

3

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

publication date

1 January 2005

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

Antiviral Chemistry & Chemotherapy

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

16

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

5

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

295-302

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

Treatment of antiretroviral-drug-resistant HIV-1 infection

1 reference

https://api.crossref.org/works/10.1177%2F095632020501600502

21 January 2018

Mechanisms of virologic failure in previously untreated HIV-infected patients from a trial of induction-maintenance therapy. Trilège (Agence Nationale de Recherches sur le SIDA 072) Study Team).

1 reference

https://api.crossref.org/works/10.1177%2F095632020501600502

21 January 2018

Molecular impact of the M184V mutation in human immunodeficiency virus type 1 reverse transcriptase

1 reference

https://api.crossref.org/works/10.1177%2F095632020501600502

21 January 2018

Guidelines for using antiretroviral agents among HIV-infected adults and adolescents

1 reference

https://api.crossref.org/works/10.1177%2F095632020501600502

21 January 2018

Antiretroviral-drug resistance among patients recently infected with HIV.

1 reference

https://api.crossref.org/works/10.1177%2F095632020501600502

21 January 2018

Absence of zidovudine resistance in antiretroviral-naive patients following zidovudine/lamivudine/protease inhibitor combination therapy: virological evaluation of the AVANTI 2 and AVANTI 3 studies

1 reference

https://api.crossref.org/works/10.1177%2F095632020501600502

21 January 2018

Anti-human immunodeficiency virus and anti-hepatitis-B virus activities and toxicities of the enantiomers of 2'-deoxy-3'-oxa-4'-thiocytidine and their 5-fluoro analogues in vitro

1 reference

https://api.crossref.org/works/10.1177%2F095632020501600502

21 January 2018

Thymidine analogue reverse transcriptase inhibitors resistance mutations profiles and association to other nucleoside reverse transcriptase inhibitors resistance mutations observed in the context of virological failure

1 reference

https://api.crossref.org/works/10.1177%2F095632020501600502

21 January 2018

Highly active antiretroviral therapy decreases mortality and morbidity in patients with advanced HIV disease

1 reference

https://api.crossref.org/works/10.1177%2F095632020501600502

21 January 2018

Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators

1 reference

https://api.crossref.org/works/10.1177%2F095632020501600502

21 January 2018

A novel phenotypic drug susceptibility assay for human immunodeficiency virus type 1

1 reference

https://api.crossref.org/works/10.1177%2F095632020501600502

21 January 2018

The prevalence of antiretroviral drug resistance in the United States

1 reference

https://api.crossref.org/works/10.1177%2F095632020501600502

21 January 2018

Prevalence of HIV-1 resistant to antiretroviral drugs in 81 individuals newly infected by sexual contact or injecting drug use. Investigators of the Quebec Primary Infection Study.

1 reference

https://api.crossref.org/works/10.1177%2F095632020501600502

21 January 2018

Lamivudine (3TC) resistance in HIV-1 reverse transcriptase involves steric hindrance with beta-branched amino acids

1 reference

https://api.crossref.org/works/10.1177%2F095632020501600502

21 January 2018

Resistance of HIV-1 to multiple antiretroviral drugs in France: a 6-year survey (1997-2002) based on an analysis of over 7000 genotypes

1 reference

https://api.crossref.org/works/10.1177%2F095632020501600502

21 January 2018

Drug resistance and drug combination features of the human immunodeficiency virus inhibitor, BCH-10652 [(+/-)-2'-deoxy-3'-oxa-4'-thiocytidine, dOTC].

1 reference

https://api.crossref.org/works/10.1177%2F095632020501600502

21 January 2018

Analysis of prevalence of HIV-1 drug resistance in primary infections in the United Kingdom

1 reference

https://api.crossref.org/works/10.1177%2F095632020501600502

21 January 2018

Broad Nucleoside Reverse‐Transcriptase Inhibitor Cross‐Resistance in Human Immunodeficiency Virus Type 1 Clinical Isolates

1 reference

https://api.crossref.org/works/10.1177%2F095632020501600502

21 January 2018

Identifiers

10.1177/095632020501600502

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q44552532&oldid=2027702893"